Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study
International Journal of Molecular Sciences · 15.05.2026 · 27 (10) · 4406
DOI: 10.3390/ijms27104406 ↗Kurz gefasst
Klinische Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.05.2026. Verfasst von Sarah A Blomquist und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Qualia Life Sciences, Carlsbad, CA 92008, USA. Hauptthemen laut MEDLINE: Biomarkers, Cellular Senescence, Dietary Supplements, Proteomics. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qualia Life Sciences.
Abstract (Originalsprache)
Cellular senescence drives aging and age-related disease through the accumulation of senescent cells and their senescence-associated secretory phenotype (SASP). Emerging evidence suggests intermittent (“hit-and-run”) senolytic interventions may improve healthspan by reducing senescent cell accumulation and the SASP. Healthy adults aged 45–79 were recruited for a decentralized, single-arm pilot study (NCT06953518) evaluating 2 days of nutraceutical supplementation (Qualia Senolytic). Fingerstick blood samples and validated quality of life (QoL) questionnaire data were collected on days 0 and 7. Primary outcomes were SASP biomarkers measured by the Olink® Target 48 Cytokine panel, including tumor necrosis factor (TNF), interleukin-1 beta (IL-1β), interleukin-8 (CXCL8), and vascular endothelial growth factor A (VEGFA). Protein data were analyzed using linear mixed models and Wilcoxon signed-rank tests. Seventy-one adults enrolled and 53 (74.6%) provided paired protein samples. No significant changes occurred in primary outcomes. Exploratory unadjusted analyses revealed significant reductions in the established senescence chemokines CXCL9 and CXCL10, as well as CCL8 and CXCL11, and increases in interleukin-17F and oncostatin M. QoL significantly improved without safety concerns, though results are expectation-sensitive. Preliminary findings support the feasibility of this decentralized approach and identify candidate SASP biomarker signals in healthy adults warranting validation in randomized, placebo-controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Development, Qualia Life Sciences, Carlsbad, CA 92008, USA.
- OvationLab, Richmond, VA 23220, USA.
- Department of Family and Community Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- LuminoDx Inc., San Diego, CA 92121, USA.
ORCID-Profile: Sarah A Blomquist, Christopher R D'Adamo
Förderung
- Qualia Life Sciences
Zitieren
APA
Blomquist, S. A., Kelly, G., D'Adamo, C. R., Han, C., Parker, H., Adães, S., Gardner, C. R., Ardagh, A., Ramer, S., & Scuba, W. (2026). Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study. International Journal of Molecular Sciences, 27(10), 4406. https://doi.org/10.3390/ijms27104406
Vancouver
Blomquist SA, Kelly G, D'Adamo CR, Han C, Parker H, Adães S, et al. Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study. International Journal of Molecular Sciences. 2026;27(10):4406. doi:10.3390/ijms27104406
BibTeX
@article{Blomquist2026,
author = {Blomquist, Sarah A and Kelly, Gregory and D'Adamo, Christopher R and Han, Chang and Parker, Haleigh and Adães, Sara and Gardner, Colin R and Ardagh, Abhimanyu and Ramer, Shawn and Scuba, William},
title = {Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {10},
pages = {4406},
doi = {10.3390/ijms27104406}
}
EUVIMED